Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups.

Saved in:
Bibliographic Details
Title: Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups.
Authors: Knabe R; Department of Medicine III, University Hospital Munich (LMU), Munich, Germany., Muller P; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.; Department of Emergency Medicine, University Hospital Berlin (Charité), Berlin, Germany., Schliemann C; Department of Medicine A, University Hospital Münster, Münster, Germany., Hanoun M; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Unglaub JM; Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Weinbergerová B; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University Brno, Brno, Czech Republic., Mayer J; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University Brno, Brno, Czech Republic., Krekeler C; Department of Medicine A, University Hospital Münster, Münster, Germany., Krause SW; Department of Hematology and Medical Oncology, Uniklinikum Erlangen, Erlangen, Germany., Kaufmann M; Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch-Hospital, Stuttgart, Germany., Kraus S; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany., Steffen B; Department of Hematology and Oncology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany., Modemann F; Department of Oncology, Hematology and Bone Marrow Transplantation with Division of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Subklewe M; Department of Medicine III, University Hospital Munich (LMU), Munich, Germany.; Partner Site Munich, German Cancer Consortium (DKTK), Munich, Germany.; Gene Centre, Munich, Germany.; German Cancer Research Centre, Helmholtz Association and German Centers for Health Research, Heidelberg, Germany., Bücklein V; Department of Medicine III, University Hospital Munich (LMU), Munich, Germany., Kunz WG; Department of Radiology, University Hospital Munich (LMU), Munich, Germany., Rudelius M; Department of Pathology, University Hospital Munich (LMU), Munich, Germany., von Bergwelt-Baildon M; Department of Medicine III, University Hospital Munich (LMU), Munich, Germany.; Partner Site Munich, German Cancer Consortium (DKTK), Munich, Germany.; German Cancer Research Centre, Helmholtz Association and German Centers for Health Research, Heidelberg, Germany., Gutmair K; Institute for Medical Information Processing, Biometry, and Epidemiology, IBE, LMU Munich, Munich, Germany., Hoster E; Institute for Medical Information Processing, Biometry, and Epidemiology, IBE, LMU Munich, Munich, Germany., Herold T; Department of Medicine III, University Hospital Munich (LMU), Munich, Germany., Röllig C; Department of Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany., Spiekermann K; Department of Medicine III, University Hospital Munich (LMU), Munich, Germany.; Partner Site Munich, German Cancer Consortium (DKTK), Munich, Germany.
Source: Blood advances [Blood Adv] 2025 Jul 08; Vol. 9 (13), pp. 3336-3339.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024014570